Accessibility Menu
Adagene logo

Adagene(NASDAQ) ADAG

Market Cap$151.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-89%
5 Year-84%
1 Year+61%
1 Month-25%
$3.50
+9.38%
+0.30Today
Adagene last closing stock price
MetricPriceDate
Last closeUSD 3.202026-07-24
Adagene stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.86%USD 3.592026-07-17
1 month-24.71%USD 4.252026-06-24
3 month-13.28%USD 3.692026-04-24
Year to date+69.31%USD 1.892025-12-31
1 year+60.8%USD 1.992025-07-24
3 year+140.62%USD 1.332023-07-25
5 year-84.06%USD 20.072021-07-23
Since inception-89.33%USD 29.992021-02-09

Adagene Financials at a Glance

Market Cap

$151.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$7.80M

Net Income (TTM)

-$51.08M

EPS (TTM)

-$0.37

P/E Ratio

-8.55

Dividend

$0.00

Beta (Volatility)

0.35 (Low)

Price

$3.50

Volume

199,411.142

Open

$3.27

Previous Close

$3.53

Daily Range

$3.25 - $3.53

52-Week Range

$1.30 - $4.85

Estimated Earnings Date

Sep 2, 2026

ADAG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adagene

Adagene Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody-based therapeutics for various cancers. The company is advancing several investigational assets through human trials, aiming to address significant unmet medical needs in oncology.

Products and Services
  • ADG106: Anti-CD137 monoclonal antibody in Phase 1b/2 trials
  • ADG126 and ADG116: Anti-CTLA-4 monoclonal antibodies in Phase 1 studies
  • ADG104: Anti-PD-L1 monoclonal antibody in Phase 2 development
Growth Outlook
  • Strong pipeline with multiple assets in clinical trials
  • Recent funding rounds have bolstered cash reserves for R&D
  • Strategic partnerships may enhance market access and development speed
Financial Highlights
  • Q4 2025 revenue of $7.69 million, a significant increase from previous quarters
  • Cash and cash equivalents of $74.52 million as of December 2025
  • Current ratio of 3.07 indicates strong liquidity position
Adagene Inc. operates in the biotechnology sector, with a focus on innovative cancer therapies. The company has made significant strides in its clinical pipeline, with several promising candidates undergoing various stages of development. The recent quarterly revenue reflects a positive trend, indicating potential market acceptance of its products. Furthermore, the robust cash position allows for continued investment in research and development, positioning the company well for future growth. The strategic partnerships and collaborations may further enhance its capabilities and market reach, making Adagene an intriguing prospect in the biopharmaceutical landscape.
AI Generated • Jul 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

128

CEO

Peizhi Luo, PhD

Website

www.adagene.com

Headquarters

Suzhou, JS 215123, CN

ADAG Financials

Key Financial Metrics (TTM)

Gross Margin

92.43%

Operating Margin

-279.39%

Net Income Margin

-229.49%

Return on Equity

-48.20%

Return on Capital

-51.52%

Return on Assets

-22.56%

Earnings Yield

-11.70%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$151.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

47.39M

Volume

199.41K

Avg. Volume

220.22K

Financials (TTM)

Gross Profit

$5.78M

Operating Income

-$57.44M

EBITDA

-$52.57M

Operating Cash Flow

-$45.40M

Capital Expenditure

-$50.68K

Free Cash Flow

-$45.45M

Cash & ST Invst.

$74.52M

Total Debt

$6.26M

Adagene Performance Analysis

Adagene annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 9,281,682-8.9%
20232023-12-31USD 18,095,74795.0%
20242024-12-31USD 103,256-99.4%
20252025-12-31USD 7,691,1907348.7%
Adagene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Adagene annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.840.7%
20232023-12-31USD -0.43-76.6%
20242024-12-31USD -0.7471.8%
20252025-12-31USD -0.37-49.6%
Adagene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$7.69M

N/A

Gross Profit

$7.41M

N/A

Gross Margin

96.33%

N/A

Market Cap

$151.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.18M

N/A

Employees

128

N/A

Net Income

-$4.14M

+51.3%

EBITDA

-$5.48M

+38.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$74.52M

-22.1%

Total Debt

$6.26M

-69.9%

Accounts Receivable

$17.35K

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.19M

-74.5%

Short Term Debt

$5.07M

-68.5%

Return on Assets

-22.56%

N/A

Return on Invested Capital

-40.48%

N/A

Free Cash Flow

-$4.56M

+31.9%

Operating Cash Flow

-$4.55M

+32.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FBIOFortress Biotech, Inc.
$3.27-2.10%
GANXGain Therapeutics, Inc.
$1.86+6.29%
ACETAdicet Bio, Inc.
$8.06+3.47%
XBITXBiotech Inc.
$2.26-0.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About ADAG

What is the current price of Adagene?

Adagene is trading at $3.53 per share.

What is the 52-week range for Adagene?

Over the past 52 weeks, Adagene has traded between $1.30 and $4.85.

How much debt does Adagene have?

As of the most recent reporting period, Adagene reported total debt of $6.26M.

How much cash does Adagene have on hand?

Adagene reported $74.52M in cash and cash equivalents in its most recent financial results.

What is Adagene’s dividend yield?

Adagene does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services